WILMINGTON, N.C., March 18 /PRNewswire-FirstCall/ --
aaiPharma Inc. (Nasdaq: AAII) announced today that it is launching a new
Investor Relations information tool on its corporate web site,
http://www.aaipharma.com. This tool, in the form of frequently asked questions
(FAQs), will address the most commonly asked questions of the Company
regarding the performance of its Darvon(R)/Darvocet-N(R) brand franchise.
"The purpose of this information is to help investors understand the
different forms of data available to track product performance in the
marketplace and provide context for the measurements we use to measure our
success in the field with Darvon(R)/Darvocet-N(R)," commented Dr. Philip S.
Tabbiner, President and CEO of aaiPharma. "This is the first in a series of
improvements we are making to our web site in an effort to provide
shareholders and other constituents the information they need in a timely,
easy to use fashion."
About aaiPharma
aaiPharma Inc. is a leading, science-based specialty pharmaceutical
company with corporate headquarters in Wilmington, North Carolina. With more
than 23 years of drug development expertise and a proven sales and marketing
track record, the Company is focused on acquiring, improving and marketing
well-known, branded medicines in pain management, gastroenterology and
critical care. In addition to its branded product portfolio and robust
pipeline, aaiPharma continues to offer comprehensive drug development services
to the pharmaceutical, biotechnology, generic and device industries through
its services division, AAI International. For more information, please visit
aaiPharma's website at http://www.aaipharma.com.
Darvon(R) and Darvocet-N(R) are registered trademarks owned by aaiPharma.
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
media, Andrea L. Johnston, Vice President,
Corporate Communications, +1-910-254-7340, or investors, James B.
Sloan, Jr., Senior Vice President, Corporate Finance,
+1-910-254-7690, both of aaiPharma Inc.
|
